Cardiovascular Disease Doctors in Danville, VA Accepting Medicare

7 Cardiovascular Disease doctors found. Showing 1 - 7

Syed Aftab Ahmed, MD Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 125 Executive Dr, Suite K, Danville, VA 24541 Phone: 434-792-7471    Fax: 434-792-1087

Stephen Van Davis, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Deer Run Rd, Danville, VA 24540 Phone: 434-799-0090    Fax: 434-799-0098

Dr. David Kotlaba, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 201 S Main St, Suite 1100, Danville, VA 24541 Phone: 434-791-3009    Fax: 434-791-3228

Boshra George Zakhary, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 201 S Main St Ste 1100, Danville, VA 24541 Phone: 434-792-9110    Fax: 434-799-6074

Dr. Sumeet Subherwal, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1040 Main St, Danville, VA 24541 Phone: 434-792-1433    Fax: 434-797-2807

Dr. Gary Price Miller, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 158 Executive Drive, Danville, VA 24541 Phone: 434-791-1088    Fax: 434-799-8525

Dr. Brian Wittmus Zagol, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 158 Executive Dr, Danville, VA 24541 Phone: 434-791-1088    Fax: 434-799-8525

News Archive

Roche announces new dosing strategy

Roche has announced results from a study demonstrating that the new boosted dosing regimen for its protease inhibitor Invirase(R) (saquinavir 1000 mg with ritonavir 100 mg twice-daily) has no significant interactions when it is co-administered with tenofovir disoproxil fumarate (300 mg once-daily).

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

Demand for advanced multiparameter monitoring devices increasing with rising disease incidence

Rising incidences of chronic illnesses, heart disorders and hypertension are widening the patient population pool in Europe, creating demand for technologically advanced multiparameter monitoring devices. Lack of reimbursement, however, remains a crucial issue restraining adoption of most high-end imaging modalities.

SANImagenetix first quarter net sales decrease 36%

SANImagenetix, Inc. announced today results for the three months ended June 30, 2010. Net sales decreased 36% for the first quarter of fiscal year 2011 to $1,085,000 from $1,702,000 for the same period of last year. Net loss for the first quarter was $604,000 or $.05 per share compared to a loss of $415,000 or $.04 per share for the same period of the prior fiscal year.

Anti-abortion protestors marking Roe v. Wade anniversary with D.C. March

Meanwhile, a coalition including business interests, state officials and educational institutions is gelling around efforts to fight the health law's contraception mandate.

Read more Medical News

› Verified 8 days ago